Combination therapy for newly diagnosed high-grade glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a newly diagnosed high-grade glioma (WHO grade 3 or 4) confirmed by biopsy or surgery.
- You can be between 3 and 39 years old, depending on the type of tumor.
- You must not have received any prior cancer treatment except surgery.
- You need to have enough tumor tissue available from your surgery for testing.
- You must be in good enough health to walk or be in a wheelchair, with a performance score of 50 or higher.
- Your blood counts and organ function (kidney, liver) must meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial tests a new drug combination for people with newly diagnosed glioblastoma, a type of brain cancer. It adds an immunotherapy drug (adebrelimab) to standard chemotherapy, and some participants also receive hyperbaric oxygen therapy, which may help the treatment work better.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two immunotherapy drugs (relatlimab and nivolumab) for newly diagnosed high-grade gliomas and brainstem tumors that have specific genetic mutations. The goal is to see if this treatment approach can help your immune system fight the cancer.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.